Immunotherapy for Renal Cell Carcinoma by Itsumi, Momoe & Tatsugami, Katsunori
Hindawi Publishing Corporation
Clinicaland Developmental Immunology
Volume 2010, Article ID 284581, 8 pages
doi:10.1155/2010/284581
Review Article
Immunotherapy forRenalCellCarcinoma
Momoe Itsumiand KatsunoriTatsugami
Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku,
Fukuoka 812-8582, Japan
Correspondence should be addressed to Katsunori Tatsugami, ktatsu@uro.med.kyushu-u.ac.jp
Received 2 July 2010; Accepted 29 November 2010
Academic Editor: Eiji Matsuura
Copyright © 2010 M. Itsumi and K. Tatsugami.Thisisanopenaccessarticledistributed under theCreative CommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Immunotherapy plays a signiﬁcant role in the management of renal cell carcinoma (RCC) patients with metastatic disease
because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the
treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and eﬀectiveness
of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically
signiﬁcant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical
improvement.Recently, the importanceofimmuneregulation by antigen-presenting cells (APC) andregulatory Tcells (Treg cells)
has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of
immunotherapy for RCC.
1.Introduction
Renal cell carcinoma (RCC), a glandular carcinoma, ac-
counts for approximately 85%–95% of adult malignant
kidney cancercases [1]. Patients with advanced or metastatic
disease have a poor prognosis, with a 5-year survival rate
of less than 15%. Surgical treatment is eﬀective, even in
patients with advanced or metastatic RCC, because of its
high resistance to chemotherapy and radiation therapy.
Immunotherapyusing interferon (IFN)-αand/orinterleukin
(IL)-2 has shown promising anti-tumor activity in RCC
[2–4]. However, these cytokines have a positive eﬀect in
only 10%–20% of cases [5]. Like melanoma, RCC is classed
as an immunogenic tumor based on its response rate to
immunotherapy, the incidence of spontaneous regression,
and the high level of tumor T cell inﬁltration. Despite its
immunogenicity, only a few CD8+ cytotoxic-T-lymphocytes
(CTLs), which can eﬃciently eliminate RCC cells, have been
isolated [6]. This is in line with the small number of RCC-
associated antigens that have so far been identiﬁed, thereby
limiting the trials of candidate vaccines in these patients
[7, 8].
Recently, tumor immunotherapy using DC has been
shown to have therapeutic potential for malignant tu-
mors. Moreover, nonmyeloablative stem cell transplantation
(NST), which was developed for the treatment of leukemia,
is eﬀective against RCC [9, 10] and other solid tumors [11].
In this review, we discuss the current status of cell-mediated
tumor-speciﬁc and nonspeciﬁc immunotherapy for RCC.
2.Tumor-SpeciﬁcandNon-Speciﬁc
Immunotherapy
In vivo studies show that cellular immunity mediated by T
cells, natural killer (NK) cells or NK T cells plays a central
role in the eradication of tumors. Since 1980, many attempts
have been made to administer anti-tumor cells to cancer
patients. In the late 1980s, human tumor antigens were
identiﬁedandtumor-speciﬁccellularimmunitymediatedvia
these tumor antigens received a lot of attention. Also, the
administration of cytokines that activate cellular anti-tumor
responses, including those mediated by T cells and NK cells,
has been the subject of much research. It is thought that
IFN-α induces Th1 cytokine production, thus promoting
anti-tumor activity by cells that elicit cytotoxicity by acting
directly on the tumor [12].2 Clinical and Developmental Immunology
Table 1: Immunotherapy using inactivated tumor cells and a gene modiﬁed tumor vaccine (GMTV).
Authors Vaccine Adjuvant Patients Duration of PFS/RFS Results
Galligioni Auto irrad tumor BCG 120 13mo 5-year DFS 63%
(control 72%) P = .21
Schwaab Auto irrad tumor BCG, IFN-α,I F N - γ 14 — 3 MR, 5 SD, l PD
Dillman Auto irrad tumor BCG, IFN-α,I F N - β 25 2.4mo median survival 33.4mo,
GM-CSF, Cy 5-year survival 43%
Jocham Auto lysate None 379 47.8mo 5-year PFS 77.4%
(control 67.8%) P = .02
Dudek Auto LMI None, Cy, Cy+IL-2 31 2.8mo N o n e :5S D ,C y :4S D ,
Cy+ IL-2: 1PR 3 SD
May Auto lysate None 495 — 5 year,10 year OS: 80.6, 68.9%
(control 79.2, 62.1%) P = .066
Simons Auto irrad tumor None 16 — 1 PR
+G M - C S F
Wittig Auto irrad tumor Oligonucleotides 1 0 — 1C R ,1P R ,1M R ,2S D ,5P D
+G M - C S F ,I L - 7
Antonia Auto irrad tumor IL-2 15 — 2 PR, 2 SD
+B 7 . 1g e n e
Tani Auto irrad tumor None 6 — 1 SD, l MR
+G M - C S F
Pizza Auto irrad tumor None 30 170.5 dy 1 CR, 4 PR, 9 SD
+I L - 2
Moiseyenko Auto irrad tumor None 3mo 1 SD, l MR
+ tag7/PGPR-S gene 4
Fishman Auto irrad tumor I L - 2 3 9 — 1C R ,2P R ,2 4S D
+B 7 . 1g e n e
Buchner Auto irrad tumor None 12 5.3mo PFS 5.3 mo, OS 15.6mo
+ B7.1, IL-2 gene
LMI: large multivalent immunogen, Cy: cyclophosphamide, DFS: disease-free survival, Os: overall survival, PR: partial response, MR: mixed response, SD:
stable disease, PD: progressive disease, PFS: progression-free survival, RFS: recurrence-free survival.
IL-2 is a growth/diﬀerentiation factor for NK cells and
T cells, which induces and maintains the cytotoxicity, both
these cell types [13]. Because cytokine treatment induces
nonspeciﬁc anti-tumor activity, it is known as nonspeciﬁc
immunotherapy.
In 1984, Mule et al. reported lymphokine-activated killer
(LAK)celltreatment oftumorsusing inducibleculturedcells
[14]. Culturing immune cells isolated from a cancer patient’s
peripheral blood, or excised tumor tissue, with IL-2 causes
them to diﬀerentiate into LAK cells. Since the second half
of the 1980s, treatment using LAK cells has been attempted
in several facilities [15, 16]. However, because the treatment
method causes severe side eﬀects, it was never established
as an eﬀective treatment method. LAK cells have no tumor
speciﬁcity because they are induced in culture in response to
IL-2 alone and not by tumor antigens. Thus, it was thought
thattheadoptivetransferofLAKcellsmightresultindamage
to normal host cells in vivo.
Since Van Der Bruggen et al. identiﬁed tumor antigens
that were speciﬁcally recognized by T cells in a melanoma-
bearing patient [17], research became more focused on
tumor-speciﬁc immunotherapy. Though LAK cells, CTLs,
macrophages, NK cells and NKT cells are all involved in host
immune response against tumors, CTLs are now thought to
be one of the most important factors responsible for anti-
tumor immunity.
3.ImmunotherapyUsing Inactivated
TumorCellsand Gene ModiﬁedTumor
Vaccines (GMTV)
Immunotherapy using inactivated tumor cells or tumor
lysates is based on the idea that tumor cells express anti-
gens that induce anti-tumor immune responses [18–22]
(Table 1). Because immunotherapy using tumor cells is
relatively straightforward, Jocham et al. undertook a large-
scalerandomizedcontrolledtrialandreportedthatthe“non-
replaced phase” after surgery for kidney cancer was extended
by an autologous tumor vaccine [20] .T h ep e r c e n t a g eo f
vaccinated patients showing no disease progression 5 years
after treatment was 77.4% compared with 67.8% of the
controls.
Both cytokines and antigen-presenting cells are impor-
tant for the induction of eﬀective immune responses
[23]. Thus, GMTV was used to introduce virus-expressingClinical and Developmental Immunology 3
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Figure 1: CTL induction by Apcs. Antigens are taken up and degraded into peptide fragments by antigen presenting cells (APC), such as
immature DC. At some point on their path to the cell surface, newly synthesized MHC class II or I molecules bind the peptide antigen
fragmentsandtransportthepeptides tothecellsurface.CD8+ Tcellsrecognizingtheantigenexpressed by weaklycostimulatorycellsbecome
activated only in the presence of CD4+ T cells bound to the same APC. This happens via CD4+ T cells recognizing antigens presented by
APCs and being triggered to induce increased levels of costimulatory activity by the antigen-presenting cell. The CD4+ T cells also produce
increased amounts of IL-2, which drives CD8+ Tc e l lp r o l i f e r a t i o n .C D 8 + T cells then become cytotoxic T lymphocytes (CTL).
cytokines, or costimulatory molecules, into tumor cells
(Table 1)[ 18–22, 24–33]. GMTV-immunotherapy introduc-
ing cytokine transgene, such as GM-CSF or IL-2, or costim-
ulatory molecule transgene such as B7-1 into autologous ir-
radiatedtumors,hasbeencarriedout.However,thesestudies
were disappointing in terms of a signiﬁcant clinicalresponse,
such as tumor regression. Though the use of multiple tumor
antigens should induce a greater immune response, one
cannot rule out the possibility of unintentionally inhibiting
anti-tumor immunity or of eliciting non-speciﬁc immune
responses.
4.Peptide-BasedImmunotherapy
Since the development of the SEREX method, which enables
the identiﬁcation of tumor antigens from cDNA libraries,
many peptide-based vaccination studies have been under-
taken. Because the eﬀective induction of anti-tumor immu-
nity using single peptides is diﬃcult, MHC class II peptides
have been used along with adjuvants (Table 2)[ 34–40].
HSPPC-96 (vitespen) is a heat shock protein. It is a peptide
complex, in which the heat shock protein plays the role of
an adjuvant. However, a recent randomized phase III study
suggested that this complex did not improve recurrence-
free survival rates [41]. Further studies are required to see
whether antigen-speciﬁc T cells homogeneously induced by
a single tumor antigen can be eﬀective against a diverse
population of tumor cells.
5.DC-Based Immunotherapy
Antigens processed within the proteasome of tumor cells are
presented on major histocompatibility antigen (MHC) class
I molecules of tumor cell as tumor antigen peptides that
CTLs recognize, thus triggering CTL-mediated cytotoxicity.
However, CTLs are not activated by direct recognition
of the antigens expressed by tumor cells; they need help
from dendritic cells (DCs) and CD4+ helper T cells. To
activate a CD8+ T cell to become a CTL, engagement of
the T cell receptor with a peptide antigen presented by an
MHC class I molecule is not enough. The T cell must also
recognize a costimulatory molecule (e.g. CD80 or CD86)
(Figure 1). Moreover, antigen presenting cells (APCs) are
activated through their interaction with CD4+ T cells, and
then they express various costimulatory molecules. DCs are
the most well-known and eﬃcient APCs and are present
in various tissues, including lymphoid and nonlymphoid
organs and the blood, where they take up both particulate
and soluble antigens before migrating to the lymph nodes
to induce immune responses. Subsequently, DCs present
a n t i g e nt oTc e l l si nt h el y m p hn o d e sa n di n d u c ea n t i g e n -
speciﬁc immune responses, includingthe induction of CTLs.
DCs also present antigen to other cells, including NK cells.
Clinical trials of DC therapy are listed in Table 3 [23,
35, 36, 42–59]. Although immunotherapy using DCs and
nonautologous tumor cells seems to induce host immune
cells to recognize tumor cells, there is still the possibility of
alloreactive immune responses induced by nonself-antigens.4 Clinical and Developmental Immunology
Table 2: Peptide-based immunotherapy.
Authors Stage Vaccine Adjuvant Patients Duration of
PFS/RFS Results
Uemura mRCC CA9-derived peptide Incomplete Freund’s
adjuvant 23 12.2mo 3 PR, 6SD
Iiyama mRCC WT 1-peptide Incomplete Freund’s
adjuvant 3— 2 S D
Suekane mRCC 4 diﬀerent peptides None, IFN-α,I L - 2 1 0 2 3w k 6S D
Wood cT1b-T4N0M0 or T
ant N1-2 M0 HSPPC-96 (vitespen) None 728 1.9yr No diﬀerence in
recurrence-free survival
Jonasch mRCC HSPPC-96 (vitespen) None 60 65dy 2 CR, 2 PR, 7 SD
mRCC: metastatic RCC, PADRE: pan-MHC class II binding peptide, Auto mDC: autologous mature DC, CR: complete response, PR: partial response, SD:
stable disease, PFS: progression-free survival, RFS: recurrence-free survival.
Because nonautologous DCs (allo-DCs) may be attacked by
the host immune system, immunotherapy using autologous-
DCs (auto DCs) might be more eﬀective in vivo. To date, all
reports regarding DC treatment are of phase I/II trials incor-
porating diﬀerent methodologies. Although delayed-type
hypersensitivity reactions in response to tumor cell lysates
or keyhole limpet hemocyanin (KLH) and the production
of IFN-γ by antigen-speciﬁc lymphocytes were observed, the
number of patients showing a positive clinical response was
still low.
We also used IFN-α as an adjunctive agent for DC
therapy.Aspreviouslynoted,IFN-αinducedanenvironment
conducive to DC activation and enhanced migratory com-
petence [60, 61]. We evaluated the eﬃcacy of DC-therapy
in combination with IFN-α in patients with advanced RCC.
After 4 months of vaccinations, ﬁve patients had stable
disease and two had progressive disease. In six patients,
the time-to-progression was prolonged compared with that
seen after previous cytokine treatment. Because cytokine
combination therapy induces the proliferation and mainte-
nance of DC-activated T cells, combination therapy using
IL-2 is reasonable. However, Oosterwijk et al. reported that
combination therapy with IL-2 plus DCs was no more
eﬀective than DCs alone [44]. Recently, it was reported that
IL-2 participates in the maintenance of regulatory T cells
(Tregs), which suppress immune responses [62]. Further
study of the role of IL-2 in immunotherapy is required.
6.Nonmyeloablative StemCell
Transplantation(NST)
Though NST was developed for the treatment of leukemia,
it began to gain attention as a treatment for solid tumors.
In 2000, Childs et al. performed NST on 19 renal carcinoma
patients and reported a success rate 53%; three patients were
in complete remission and seven patents were in partial
remission. Previous reports have highlighted the important
role played by cellular anti-tumor immunity, including that
mediated by donor T cells in graft versus host disease
(GVHD) and the graft versus tumor eﬀect (GVT); the ap-
pearance of GVHD induced by transplantation of donor T
cellsis inversely correlated with the rate oftumorrecurrence.
Recurrence is especially high in T cell-depleted stem cell
transplants, and the administration of donor lymphocytes
eﬀectively reduces the incidence of recurrence [63, 64].
Donor T cells induce GVHD/GVT against recipient anti-
gens, including MHC molecules, minor histocompatibility
antigens and tumor cell-speciﬁc antigens. An eﬀective GVT
response can be induced if the antigen distribution between
normal cells and tumor cells can be identiﬁed, and if donor
T cell responses against normal cells can be controlled. Thus,
in NST, the mechanism by which tumor speciﬁc immunity is
induced is very important, and a recent study attempted to
address the question of how this response was activated [65].
When the patient receives immunosuppressive treatment
for GVHD, it might also cause suppression of the associated
anti-tumor eﬀects. In these patients, the diﬀerentiation of
mononuclear cells into DCs is inhibited in vitro [66]. There-
fore, when treating a patient with NST, one should bear in
mind possible aggravation of the neoplasm by immunosup-
pressive therapy directed against GVHD.
7.RegulatoryCD4+ T Cellsand theTumor
Recent research shows that CD4+ T cells constitutively ex-
pressing the IL-2 receptorα-chain (CD25)act in a regulatory
capacity by suppressing the activation and function of other
T cells [67]. Their physiological role is to protect the host
against the development of autoimmunity by regulating
immune responses against antigens expressed by normal
tissues [68, 69]. Since tumor antigens are largely self-
antigens, these so-called Treg cells may also prevent the
tumor-bearing host from mounting an eﬀective antitumor
immune response. Previous studies haveshown that elevated
numbers of CD4+CD25+ Tregs can be found in patients with
advanced cancer [70] and that high Treg frequencies are
associated with reduced survival [71]. In our experiments
into cytokine therapy for RCC patients, the number of
CD4+ and FoxP3+Treg cells was signiﬁcantly decreased
after IFN-α treatment, and Treg cell levels before treatment
correlated with the clinical response [72]. The important
role of CD4+CD25+ Tregs in controlling tumor growth was
further highlighted by the demonstration that depletion of
Tregs using anti-CD25 antibodies evokes eﬀective antitumor
immunity in mice [73, 74]. Dannull et al. used a recom-
binant IL-2:diphtheria toxin conjugate (DAB389IL-2; alsoClinical and Developmental Immunology 5
Table 3: DC-based immunotherapy.
Authors Antigen DC Adjuvant Patients Duration of
PFS/RFS Results
Oosterwijk-Wakka Auto lysate Auto imDC KLH/IL-2 12 — 8 SD, 4 PD
Marten Auto lysate Auto mDC KLH 15 — 1 PR, 7 SD, 7 PD
Holtl Auto & Allo lysate Auto mDC KLH 27 20.4mo 2C R ,1P R ,7
SD, 17 PD
Azuma Auto lysate Auto imDC KLH 3 — 1 NC, 2 PD
Marten DC/auto tumor
fusion Allo mDC — 12 — 4 SD, 8 PD
Su tumor RNA Auto imDC — 10 — not evaluated
Gitliz Auto lysate Auto imDC — 12 — 1 PR, 3 SD, 8 PD
Barbuto DC/auto tumor
fusion Allo mDC — 19 5.7mo 30 R, 14 SD, 2
PD
Avigan DC/auto tumor
fusion A u t oi m D C K L H 1 3 4 . 2m o 5S D ,8P D
Pandha Allo lysate Auto imDC KLH 5 — 2 SD
Arroyo Auto lysate Auto mDC KLH 5 9.6mo (5–16) 3 SD
Holtl Auto & Allo TuLy Allo mDC KLH/Cy 20 22.3mo 2M R ,3S D ,1 5
PD
Wierecky MUC-1 peptide Auto mDC PADRE 20 10.8mo (4–24) 1C R ,2M R ,2
PR, 5 SD, 10 PD
Bleumer CA9 peptide Auto mDC KLH CA9 class
II peptide 6— 6 P D
Wei DC/auto tumor
fusion Auto mDC IL-2 10 7mo (5–12) 1 PR, 3 SD, 6 PD
Matsumoto Auto lysate Auto mDC KLH 3 — 1 SD, 2 PD
Kim Auto lysate Auto mDC KLH 9 5.2mo 1 PR, 5 SD, 3 PD
Berntsen
Lysate or surviving
and telomerase
peptides
Auto mDC IL-2 27 2.7mo 13 SD, 14 PD
Tatsugami Auto TuLy Auto mDC IFN-α 7 7 . 8m o 5S D ,2P D
Zbou DC/auto tumor
fusion Allo mDC — 10 — 1 PR, 6 SD, 3 PD
Cy: cyclophosphamide, PADRE: pan-MHC class II binding peptide, Auto mDC: autologous mature DC, Allo imDC: allogeneic immature DC CR: complete
response, PR: partial response, MR: mixed response, SD: stable disease, OR: objective response, PD: progressive disease, PFS: progression-free survival, RFS:
recurrence-free survival.
known as denileukin diftitox and ONTAK) to eliminate
CD25-expressing Tregs in metastatic RCC patients, and re-
ported that depletion of Tregs in RCC patients followed by
vaccination with tumor RNA-transfected DCs led to im-
proved stimulation of tumor-speciﬁc T cells compared with
vaccination alone [75]. It will be critical to collect accurate
information regarding Tregs to address the clinical eﬃcacy
of such strategies in cancer patients.
8.Conclusions
The use of immunotherapy using cultured cells, such as
DCs, to treat large numbers of patients, and the conduction
of large-scale studies are diﬃcult because of the problems
associated with the need for adequate culture facilities and
appropriate culture techniques. Because of the complexity of
the immune responses involved, it is diﬃcult to evaluate the
eﬃcacy of immunotherapy compared with other treatments.
However, as it is clear that the immune system plays a
signiﬁcant role in the control of tumors, continued analysis
of the mechanisms involved in tumor immunity and the
development of new immunotherapies are vital.
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